Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
about
Rifaximin for people with hepatic encephalopathyManagement of overt hepatic encephalopathySpontaneous bacterial peritonitis: The clinical challenge of a leaky gut and a cirrhotic liverHepatic Encephalopathy: From the Pathogenesis to the New Treatments.Ammonia toxicity to the brain.Management of Neurologic Manifestations in Patients with Liver Disease.Persistent immune activation in chronic HIV infection: do any interventions work?Impact of rifaximin on the frequency and characteristics of spontaneous bacterial peritonitis in patients with liver cirrhosis and ascitesHepatobiliary Quiz (Answers)-14 (2015).Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-AnalysisImpact of pretransplant hepatic encephalopathy on liver posttransplantation outcomes.Polyethylene Glycol and Lactulose versus Lactulose Alone in the Treatment of Hepatic Encephalopathy in Patients with Cirrhosis: A Non-Inferiority Randomized Controlled Trial.Disaccharides in the treatment of hepatic encephalopathy.Update on management of patients with overt hepatic encephalopathy.Pathophysiology and management of hepatic encephalopathy 2014 update: Ammonia toxicity and hyponatremia.Lactulose vs polyethylene glycol 3350--electrolyte solution for treatment of overt hepatic encephalopathy: the HELP randomized clinical trial.Contemporary Understanding and Management of Overt and Covert Hepatic Encephalopathy.Spontaneous bacterial peritonitis by Pasteurella multocida under treatment with rifaximin.A randomized, double-blind, controlled trial comparing rifaximin plus lactulose with lactulose alone in treatment of overt hepatic encephalopathy.l-ornithine-l-aspartate for hepatic encephalopathy in patients with cirrhosis: a meta-analysis of randomized controlled trials.
P2860
Q24187627-795697BB-F9B7-4FAE-A966-AF592EF439BCQ26830789-703EDA76-A878-4CF5-BAEF-A234376D6060Q27001540-9B916B1A-F498-44D5-A7C5-17CE15CDF9A4Q30381016-898EBDAA-5734-4A1D-8DD9-DEEC6BB1E284Q30575263-E881E1D8-EF89-4548-B42E-962D9414F028Q31108752-B0A246FF-CC96-4CF7-85E8-079787AD085CQ34851102-5C184B80-EB47-4BDF-8395-161A8E0F2164Q35143004-229B1762-4B0E-4E24-AF9D-164A55B230C7Q35818316-35449677-3D53-41E3-81CC-57DB209F37E9Q36802060-4A11D792-D776-4B00-9781-02D00483C899Q37353473-4C859D66-1CC3-4415-9117-AD83B5C0953CQ37641048-39B800C8-E45B-47A7-B130-EA47A7160DCBQ38086120-BE7E3ECF-A072-4E73-8790-62E534F34424Q38129187-591A4FB2-BEF9-4CF5-9411-56D388E25E1EQ38325703-6B2254EE-82C7-40FC-99C4-0D91F40A0B23Q38423365-FA193F5C-7749-4196-929A-9D5B6E9117C4Q38835093-DA085831-EB22-45A8-8277-0A48EEC83C1CQ44491619-8EC212E4-176C-4E9B-A22B-462CF4E190F2Q51222196-38C192EB-C4DC-4867-85B2-C5305D50615AQ51344453-352815AE-0F92-49F2-B8AC-323ABAF2DEB6
P2860
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@en
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@nl
type
label
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@en
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@nl
prefLabel
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@en
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@nl
P2093
P2860
P356
P1476
Rifaximin vs. conventional oral therapy for hepatic encephalopathy: a meta-analysis.
@en
P2093
Karim M Eltawil
Kevork Peltekian
Marie Laryea
Michele Molinari
P2860
P304
P356
10.3748/WJG.V18.I8.767
P407
P577
2012-02-01T00:00:00Z